#AACR20: Iovance revels in promising lung cancer data out of Moffitt as TIL therapy triggers 2 complete responses
Shrinking, or even eradicating, solid tumors has been a Holy Grail for cell therapies, whose effects so far have been limited to blood cancers. At the American Association for Cancer Research, researchers from Moffitt Cancer Center are presenting early data suggesting that tumor-infiltrating lymphocytes can do the trick for non-small cell lung cancer.
It’s a small number: two complete responses out of 13 patients who received personalized TIL therapy. But considering that these patients had progressed following treatment with Opdivo — a standard-of-care checkpoint inhibitor — and that the tumor has stayed away for almost a year, the results count as promising.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.